NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals was added to the Russell 3000 and Russell 2000 after the markets closed on June 30, the company said today.
 
Alynlam said its inclusion in these indexes reflects an interest "in the potential of RNAi for therapeutic applications, and the promise of this technology," said John Maraganore, president and CEO of Alnylam Pharmaceuticals.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.